April 2, 2020
Celltex has submitted Emergency Expanded Access Clinical Study for Subjects with Coronavirus 2019 (COVID-19) using multiple dose Infusions of Autologous Adipose-Tissue Derived Mesenchymal Stem Cells (ADMSCs)
The COVID-19 pandemic has the global medical profession working around the clock looking for vaccines and therapies. On March 21st, 2020, Celltex submitted an emergency expanded access clinical study to the United States Food and Drug Administration (FDA) that would allow patients with COVID-19 to receive infusions of autologous Adipose-tissue derived Mesenchymal Stem Cells (AdMSCs) in the US.
Learn More